Sugi Predict

Sugi Predict / Compounds / SCHEMBL2643084

SCHEMBL2643084

SCHEMBL2643084

CS(=O)(=O)c1cc(N)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ASIC3 Q9UHC3 1/20 0.38
▸ ROCK1 Q13464 1/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA6 P23280 1/20 0.35
▸ CA5A P35218 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA13 Q8N1Q1 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIP5K1C O60331 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ PI4KA P42356 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18228284 0.98 L3MBTL1 (0.41) L3MBTL1ASIC3ROCK1PIK3C3CA12
SCHEMBL24707393 0.81 L3MBTL1 (0.34) L3MBTL1ASIC3ROCK1CA12CA1
SCHEMBL30001558 0.81 L3MBTL1 (0.34) L3MBTL1ASIC3ROCK1CA12CA1
SCHEMBL24707392 0.81 L3MBTL1 (0.34) L3MBTL1ASIC3ROCK1CA12CA1
SCHEMBL30001181 0.81 L3MBTL1 (0.34) L3MBTL1ASIC3ROCK1CA12CA1
SCHEMBL12061378 0.81 CA2 (0.50) ASIC3ROCK1CA12CA1CA2
SCHEMBL2642566 0.80 GAA (0.42) L3MBTL1ASIC3PIK3C3CA12CA1
SCHEMBL26982439 0.79 ALDH1A1 (0.44) L3MBTL1ASIC3PIK3C3CA12CA1
Hydrochloric Acid SCHEMBL31287903 0.79 CA2 (0.48) ASIC3ROCK1CA12CA1CA2
SCHEMBL10920036 0.77 ROCK1 (0.40) ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110943253-A High-voltage lithium ion battery combined electrolyte additive, electrolyte and battery thereof 松山湖材料实验室 2020-03-31 — — CN claimed
EP-4647430-A1 TETRAHYDROTHIOPHENE DERIVATIVE AND USE THEREOF IN MEDICINE Haisco Pharmaceutical Group Co., Ltd. (CN) 2025-11-12 — — EP disclosed
WO-2025108234-A1 COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦药物研究院有限公司 2025-05-30 — — WO disclosed
CN-119731169-A Sodium channel regulator and application thereof 上海汇伦医药股份有限公司 2025-03-28 — — CN disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-13 — — US disclosed
CN-119504808-A Compound, preparation method and application thereof 四川科伦药物研究院有限公司 2025-02-25 — — CN disclosed
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2025-01-14 — — US disclosed
WO-2024146632-A1 TETRAHYDROTHIOPHENE DERIVATIVE AND USE THEREOF IN MEDICINE 西藏海思科制药有限公司 2024-07-11 — — WO disclosed
EP-4385979-A1 MULTICYCLIC INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 — — EP disclosed
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2010-09-30 — — US disclosed
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2010-09-30 — — US disclosed
EP-1984350-B1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2010-08-18 — — EP disclosed
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2010-02-18 — — US disclosed
US-7629362-B2 2-pyridine carboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 — — US disclosed
CN-101389622-A Pyrimidine derivatives used as pi-3 kinase inhibitors NOVARTIS AG (CH) 2009-03-18 — — CN disclosed
EP-1984350-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS Novartis AG (CH) 2008-10-29 — — EP disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 — — US disclosed
EP-1598349-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors SCN8A, SCN2A, SCN1A L3MBTL1 4406/4885ASIC3 38/4885ROCK1 4653/4885
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN1A L3MBTL1 4406/4885ASIC3 38/4885ROCK1 4653/4885
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS PIK3CA, PI4KA, PI4KB L3MBTL1 3177/4885ASIC3 4755/4885ROCK1 1118/4885
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives GCKR, GCK, HK2 L3MBTL1 4359/4885ASIC3 1100/4885ROCK1 4187/4885
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 L3MBTL1 4342/4885ASIC3 1119/4885ROCK1 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.